Success Stories-Shanghai Wellthinic Intelligent Technology Co., Ltd.

Beijing Tiantan Biological

Pharmaceutical industry

市场价:0.00

价格:0.00

As a leading enterprise in the domestic blood products industry, Chengdu Rongsheng was the first in China to build a digital factory in the biopharmaceutical industry and has comprehensively promoted this initiative within the group. Since its establishment, Huaixin Technology has fully supported Rongsheng Pharmaceutical in creating a digital factory, making digital transformation accessible and jointly creating a new, win-win ecosystem.
Astrazeneca Pharmaceuticals

Pharmaceutical industry

市场价:0.00

价格:0.00

In June 2011, Siemens signed a contract with Chengdu Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Rongsheng") for the MES project at its Chengdu factory (hereinafter referred to as the "project"). Phase I of the project was successfully launched and operated in parallel in December 2012, and Phase II was successfully launched and operated in parallel at the end of September 2013. The entire MES system is expected to officially achieve independent electronic operation in August 2014 (compliant with the regulatory requirements of 21 CFR Part 11 for electronic records and electronic signatures), marking the entry of Rongsheng's production management into the digital era.
CanSino Biologics

Pharmaceutical industry

市场价:0.00

价格:0.00

CanSino Biologics, an "A+H" listed company, specializes in the research and production of vaccines for human use, providing solutions worldwide for the prevention and treatment of infectious diseases. It is the developer of Convidecia® (Ad5-nCoV), the only single-dose COVID-19 recombinant vaccine (adenoviral vector type 5) that has been approved for marketing in China, and Convidecia Fogou® (Ad5-nCoV), the world's first inhalable COVID-19 vaccine (adenoviral vector type 5).
Shenlian Biological

Pharmaceutical industry

市场价:0.00

价格:0.00

Shenlian Biological is a high-tech enterprise specializing in the research and development, production, and sales of veterinary biologics. It is a designated enterprise for the production of foot-and-mouth disease vaccine by the Ministry of Agriculture and Rural Affairs. The company implements comprehensive quality management and benchmarks against international quality management systems such as the European Union's GMP and the United States' FDA, with three GMP production bases. Achieving a 100% product qualification rate and a 100% supervision and spot-check qualification rate are its quality control objectives.
Beijing Minhai Biotechnology

Pharmaceutical industry

市场价:0.00

价格:0.00

Beijing Minhai Biotechnology Co., Ltd., a wholly-owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd., has four marketed vaccines: "Acellular Pertussis, Diphtheria, Tetanus and Haemophilus Influenzae Type b Combined Vaccine" (a domestic initiative), "Haemophilus Influenzae Type b Conjugate Vaccine", "Measles and Rubella Combined Live Attenuated Vaccine", and "23-Valent Pneumococcal Polysaccharide Vaccine". Eleven vaccine products have obtained clinical approval and are currently undergoing clinical trials, while multiple vaccine products are in preclinical research. The company boasts a rich and continuous product pipeline.
Allogene Therapeutics

Pharmaceutical industry

市场价:0.00

价格:0.00

Allogene Therapeutics, a global leader and pioneer in allogeneic cell therapy technology, has licensed Allogene Overland Biopharm to exclusively develop, produce, and commercialize four allogeneic CAR-T cell therapy products targeting BCMA, CD70, FLT3, and DLL3 in Greater China, South Korea, and Singapore. These products are intended for the treatment of hematological tumors such as multiple myeloma and acute myeloid leukemia, as well as solid tumors such as renal cell carcinoma and small cell lung cancer. This project provides a cleanroom Building Automation (BA) control system for their allogeneic CAR-T workshop.